Liao Yu, Wen Ziyu, Shi Minjuan, Zou Huachun, Sun Caijun
School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen 518107, China.
Shenzhen Key Laboratory of Pathogenic Microbes and Biosafety, Shenzhen Campus, Sun Yat-sen University, Shenzhen 518107, China.
Viruses. 2025 May 26;17(6):756. doi: 10.3390/v17060756.
The global HIV epidemic remains persistent, mostly because of neither a drug for its cure nor a vaccine for its prevention. An HIV vaccine is thought of as the most cost-effective biomedical intervention to eventually terminate the HIV epidemic, but it is not clinically available yet due to technical hurdles. However, beyond vaccination, increasing alternative and innovative biomedical interventions have been developed for the prevention and control of HIV infections. Herein, we discuss the challenges encountered in the innovation of biomedical interventions against HIV infections, and summarize the landscape and latest advances of these biomedical interventions to intercept the risk of HIV acquisition and transmission, aiming to provide valuable clues for exploring more out-of-the-box solutions to prevent HIV infections, thereby contributing to realizing the 2030 goal of ending the AIDS epidemic.
全球艾滋病疫情持续存在,主要原因是既没有治愈艾滋病的药物,也没有预防艾滋病的疫苗。艾滋病疫苗被认为是最终终结艾滋病疫情最具成本效益的生物医学干预措施,但由于技术障碍,目前尚未在临床上应用。然而,除了疫苗接种之外,人们还开发了越来越多的替代性和创新性生物医学干预措施来预防和控制艾滋病毒感染。在此,我们讨论了在针对艾滋病毒感染的生物医学干预措施创新中遇到的挑战,并总结了这些生物医学干预措施在拦截艾滋病毒感染和传播风险方面的情况及最新进展,旨在为探索更多预防艾滋病毒感染的创新解决方案提供有价值的线索,从而有助于实现到2030年终结艾滋病疫情的目标。